Dysbindin is a potent inducer of RhoA–SRF-mediated cardiomyocyte hypertrophy
Ashraf Yusuf Rangrez(European Bioinformatics Institute), Norbert Frey(Heidelberg University)
Cited by 31
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation
|Circulation|2020|502
RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction
|Cardiovascular Research|2014|316
U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis
|Experimental & Molecular Medicine|2013|172